Mike Cherny

Hogan answered directly, attributing confidence to geographic mix rather than any single market improving.

John described market-by-market approach to investment vs returns. Making trade-offs between high-level brand advertising vs last-mile active conversion support. Short-term can manage to expectations; long-term investing to grow the category.

John cited three drivers: product mix (no-refinement products are higher margin), productivity improvements from equipment upgrades, and volume leverage. Q4 gross margin was best since near 2021.

Joe confirmed Lumina well-accepted in both GP and ortho channels; more Luminas per account correlates with better performance. Positioned for future iterations of the platform.

Joe outlined three-pronged approach: lean into DSO growth on GP and ortho side, move marketing downstream to ZIP-code-level advertising, and deploy field force closer to retail doctors. Canada under more pressure than US.

Joe described shifting from national advertising toward working hand-in-hand with individual practices on conversion, using DSO best practices and financing solutions like HCA.

John attributed margin expansion to manufacturing efficiencies, material/logistical savings, touchless ClinCheck reducing activity, and high-margin new products like MAOB.

Joe stated competitive dynamics are stable and new innovation keeps them ahead, including ClinCheck in minutes for super users.

John provided clear volume guidance of mid-single-digit growth for the full year, noting regional variation.

Management clearly identified autoimmune and urology as priority areas while emphasizing discipline on price and timing of future deals.

CFO directly quantified the SG&A impact, separating M&A effects from organic investment in technology and teams.

Jason described specialty flywheel effect working across MSOs, BioPharma Solutions, and distribution. Other businesses (Nuclear, at-Home, OptiFreight) all connect to pharmacy capabilities. Less focused on expanding to new areas given abundant growth within existing platforms. Continued care pathways program connects at-Home with pharmacy customers.

Jason emphasized focus on controllables: service levels, capacity investments, operational quality. Not assuming outsized utilization but expecting stronger-than-historical growth. Organic and inorganic investments position business to capture whatever volume materializes.

Aaron declined to break out core distribution margins specifically. Pointed to Specialty Distribution (higher margin, double-digit growth), MSO acquisitions like Solaris, and rapidly growing Other businesses (Nuclear, at-Home, OptiFreight) as drivers of overall profit profile improvement.

Jason confirmed majority of FY25-to-FY26 delta is tariff impact. Underlying GMPD drivers (Cardinal brand growth, cost reductions, mix improvement) continuing. Headcount reductions taken in Q3.

Jason described specialty strategy as flywheel centered on community physician needs. Growing faster than market at 16% in the quarter. Still early for acquisition benefits.

Aaron attributed raise to broad-based demand strength, successful customer transition management, consistent Generics dynamics, and growing Brand/Specialty contributions.

Bob said Cencora is very happy with its broad customer portfolio across all sites of care, with good relationships across large and small customers and nothing notable to call out on renewals.

Jim outlined H2 acceleration drivers: lapping oncology customer loss in July, OneOncology accretion ramping, easier US expense comps in Q4, global specialty logistics easier comps, and MWI held-for-sale accounting benefit.

Jim confirmed successful contract negotiations with manufacturers following IRA list price changes. Maintained gross profit dollars due to value provided in supply chain. Brand pricing trends at year-end in line with expectations.

Jim broke down Q4 US OI: 25% total, 13% ex-RCA despite $15M COVID headwind and oncology customer loss. FY26 guidance still within new LRP of 6-9% even ex-RCA lapping. Not assuming same level of outperformance.

Jim confirmed confidence in long-term ranges. FY2026 moving pieces: RCA lapping (3 quarters in FY25 → 4 in FY26), oncology customer loss (1 quarter in FY25 → 4 in FY26), utilization trends, timing of capital deployment, and better expected international growth.

Jim attributed Q2 US beat entirely to organic core distribution growth. Broad-based specialty performance across physician practices and health systems. MSO expansion framed as natural evolution of specialty business.

Bob emphasized pharmaceutical-centric strategy, customer portfolio quality, and MSO services as logical next step. Did not quantify market vs company-specific growth split.

Bennett confirmed oncology customer loss is factored into guidance. Highlighted that ex-COVID vaccine headwinds, US segment OI top-end would be 8% growth.

Samad walked through the Q2 70bp drivers and the second-half offsets from volume and lapping Corewell/Fresenius dilution.

Sam broke down: 10.8% organic volume, 7% from Fresenius/Corewell, 3.8% ex those two. Rev per req up 2.5% ex-Corewell/Fresenius, driven by test per req. Jim cited AD-Detect doubling, consumer health partnerships, and advanced cardiovascular testing as key organic mix drivers.

Jim confirmed share gains from Elevance reinclusion and Sentara. 1,200+ sales reps positioning advanced testing nationally. Making inroads vs hospital outreach and physician office labs as health systems prioritize higher-return investments.

Jim said consumer channels performing above March expectations. Sam confirmed LRP assumptions (mid-single-digit revenue, high single-digit EPS, margin expansion) still intact.

Jim said majority is offensive: test per req driven by advanced diagnostics, functional medicine growth, and consumer-initiated testing up 40%. Pricing flattish at ±30bps.

Sam described ongoing payer collaboration programs redirecting work from expensive labs to Quest. Now preferred lab network provider for Optum Health's 85,000+ physicians.

Jim detailed price per test (±30bps), test per rec growth (early stages of advanced diagnostics adoption), and favorable Medicare Advantage payer mix. Sam noted test per req improvement pace will slow.

Julia explained the raise reflects moving previously corporate-held deal revenue into the segment once close confidence improved, not a change in underlying volume.

Adam detailed Dx breakdown: 5% total growth, 3% organic, 2% acquisitions. Volume 2.5% (1.5% organic, impacted by weather). Price/mix 2.6% (1.8% organic). Specialty mix driving higher test per accession and price per test. Julia confirmed full-year Dx midpoint at 5.5% with majority organic.

Adam broke down Dx revenue: 8.5% total, 6% organic, 3.5% organic volume, 2.8% price/mix. Julia confirmed unit price flat, all improvement from mix including tests per accession and Invitae annualization (more pronounced in Q3, expected to moderate in Q4).

Adam attributed accelerated organic volume to hospital deals driving geographic share gains and specialty focus areas (oncology, neurology, autoimmune) growing 3-4x faster than overall diagnostics, with spillover to routine testing.

Adam explained the 3-5% BLS range accounts for FX and potential study start delays. No study delays observed yet. One COVID trial cancellation absorbed by strong book-to-bill.

Adam detailed three margin drivers: Invitae accretion, $0.10 weather impact built in, and favorable days. Direct answer with clear framework.

Adam acknowledged volumes above historical 1-2% but attributed the excess to market share gains, expecting some normalization over time.

Brian flagged some generics favorability pulled forward that comes at the expense of later quarters; Kenny cited product-launch timing and second-half investments in growth and AI baked into the guide.

Brian highlighted technology investments driving provider value proposition, Ambient Scribe reducing burnout, Ontada data insights expansion, and SCRI clinical trial recruitment as growth vectors.

Britt noted the Q3 Rexall held-for-sale accounting comp created a 3% headwind to year-over-year growth. Momentum in specialty, health systems, and operational efficiency supports Q4 trajectory.

Brian highlighted McKesson's approach of identifying manual complicated processes across healthcare and applying network scale, pharmacy connectivity, and provider reach to streamline them, same approach used for prior authorization.

Brian described specialty growth as a combination of organic market growth, physician recruiting into existing practices, and acquisitions like FCS, demonstrating durability of the growth formula.

Brian cited contracted-program visibility and the seasonal blizzard-season pickup as drivers of H2 confidence.